{Reference Type}: Journal Article
{Title}: Radiotherapy for salivary gland cancer: REFCOR recommendations by the formal consensus method.
{Author}: Thariat J;Ferrand FR;Fakhry N;Even C;Vergez S;Chabrillac E;Sarradin V;Digue L;Troussier I;Bensadoun RJ;
{Journal}: Eur Ann Otorhinolaryngol Head Neck Dis
{Volume}: 141
{Issue}: 4
{Year}: 2024 Aug 28
{Factor}: 2.665
{DOI}: 10.1016/j.anorl.2023.11.006
{Abstract}: <B>OBJECTIVE: </B>To determine the indications for radiotherapy in salivary gland cancer and to specify the modalities and target radiation volumes.<BR><B>METHODS: </B>The French Network of Rare Head and Neck Tumors (REFCOR) formed a steering group which drafted a narrative review of the literature published on Medline and proposed recommendations. The level of adherence to the recommendations was then assessed by a rating group, according to the formal consensus method.<BR><B>RESULTS: </B>Postoperatively, radiotherapy to the primary tumor site±to the lymph nodes is indicated if one or more of the following adverse histoprognostic factors are present (risk>10% of locoregional recurrence): T3-T4 category, lymph node invasion, extraglandular invasion, close or positive surgical margins, high tumor grade, perineural invasion, vascular emboli, and/or bone invasion. Intensity-modulated radiation therapy (IMRT) is the gold standard. For unresectable cancers or inoperable patients, carbon ion hadrontherapy may be considered.<BR><B>CONCLUSIONS: </B>Radiotherapy in salivary gland cancer is indicated in postoperative situations in case of adverse histoprognostic factors and for inoperable tumors.